Characteristics of Chinese patients with genetic CJD who have E196A or E196K mutation in PRNP: comparative analysis of patients identified in the Chinese National CJD Surveillance System

Qi Shi,1,2 Kang Xiao,1 Cao Chen,1,3 Wei Zhou,1 Li-Ping Gao,1 Yue-Zhang Wu,1 Yuan Wang,1 Chao Hu,1 Chen Gao,1 Xiao-Ping Dong1,3,4

ABSTRACT

Objective Two different mutations at codon 196, namely E196A and E196K, have been reported to be related to genetic Creutzfeldt-Jakob disease (CJD). We aimed to comparatively analyse the features of Chinese patients with these two mutations from the CJD surveillance system in China.

Design and setting Comparative analysis of patients identified via the Chinese National CJD Surveillance System during the period 2006–2020.

Participants 16 Chinese patients with genetic CJD with E196A mutation and 5 with E196K mutation.

Methods Neurological examination, EEG and MRI, western blot, gene sequence, and RT-QuIC.

Results The age of onset of E196K genetic CJD cases (median of 61 years) was older than the E196A cases (median of 67 years). Generally, these two subtypes of genetic CJD were more like sporadic Creutzfeldt-Jakob disease (sCJD) clinically. The E196A cases showed more major symptoms, while those of E196K cases were restricted to dementia and mental problems. During progression, more sCJD-associated symptoms and signs gradually appeared, but none of the E196K cases showed cerebellum and visual disturbances. Typical periodic sharp wave complexes on MRI were recorded in 25% of E196A cases but not in E196K cases. sCJD-associated abnormalities on MRI, positive cerebrospinal fluid (CSF) 14-3-3 and increased CSF total tau were observed frequently, ranging from two out of three cases to four out of five cases, without a difference. Positive CSF RT-QuIC was detected in 37.5% (6 of 16) of E196A cases and 60% (3 of 5) of E196K cases. The duration of survival of E196K cases (median of 4.5 months) was shorter than the E196A cases (median of 6.5 months). Moreover, female cases and cases with young age of onset (<60 years) in E196A displayed longer survival time than male patients and cases with older age of onset (>60 years).

Conclusions This is the largest comprehensive report of genetic CJD with mutations at codon 196 to date, describing the similarity and diversity in clinical and laboratory tests between patients with E196A and with E196K mutations.

INTRODUCTION

Genetic human prion diseases, caused by different mutations in the prion protein (PrP)-encoding gene PRNP, account for approximately 10%–15% of human prion diseases. Genetic human prion diseases have various medical terms based on their clinical and neuropathological phenotypes, that is, genetic Creutzfeldt-Jakob disease (gCJD), Gerstmann-Straussler-Scheinker syndrome and fatal familial insomnia, which are closely related to different mutations within PRNP.1,2 In the context of one same disease term, such as gCJD, the clinical, neuropathological and laboratory features may vary according to mutations at different positions.3,4 Different mutations at the same position lead to substitution of different amino acids, subsequently displaying different phenotypical features, for example, mutations at codons 105, 188 and 196.4
Two different mutations at codon 196 have been reported to be related to gCJD: E196A and E196K.\(^{4-8}\) In a surveillance activity conducted by the Chinese National Surveillance for CJD (CNS-CJD) in Chinese mainland, 16 Chinese gCJD cases with E196A mutation and 5 cases with E196K mutation have been identified in the past 10 years.\(^{9,10}\) Among them, E196A gCJD was the fourth most frequently observed genetic prion disease in China (Shi \textit{et al}, unpublished data, 2020). In this study we comparatively analysed the clinical and laboratory characteristics of Chinese gCJD cases with E196A or E196K mutation. Both types of E196 gCJD revealed sporadic Creutzfeldt-Jakob disease (sCJD) like phenotype in general, while showing differences in some clinical and laboratory features.

**MATERIALS AND METHODS**

**Data collection**

As described previously,\(^{10,11}\) clinical data of patients suspected of CJD were collected by neurologists at the local hospitals while epidemiological data were collected by staff from the local provincial Chinese Centers for Disease Control and Prevention (CDCs) from 2006 to 2020. The final diagnosis was given by an expert team consisting of neurologists, epidemiologists and laboratory staff based on the diagnostic criteria for CJD issued by the Chinese National Health Commission in 2017. Follow-up surveys of patients were conducted by the staff at the centre of CNS-CJD via telephone and/or WeChat.

**Western blot for 14-3-3 protein in CSF**

Cerebrospinal fluid (CSF) samples were mixed with 5× loading buffer and boiled for 8 min. Proteins were separated in 15% sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE) and electronically transferred onto nitrocellulose membranes (Whatman, Pittsburgh, Pennsylvania, USA) by semidry method in a transfer buffer and immunoblotted with anti-14-3-3 polyclonal antibody (1:1000 dilution; Santa Cruz Biological). Reactive signals were visualised using an enhanced chemiluminescence kit (Amersham Pharmacia Biotech, Piscataway, New Jersey, USA).

**PCR and sequencing assays for the PRNP gene**

Genomic DNA was extracted from peripheral blood leucocytes using a commercial kit (QIAGEN, Germany). One hundred nanograms of the extracted DNA were amplified by PCR using specific PRNP primers (forward primer: 5′-GGCGAACTGTTGGATGGG3′ and reverse primer: 5′-CCC ACT AGG AAG ATG AGG3′).\(^{10}\) Sequencing analysis of the \textit{PRNP} gene was conducted according to standard operating procedure.\(^{10}\)

**ELISA for total tau in CSF**

The amount of protein tau in the CSF samples was quantitatively measured by a commercial ELISA kit (81572; Innometest hTau-Ag, Belgium). Briefly,\(^{12}\) 25 µL of the CSF sample were diluted with the buffer supplied by the manufacturer and added to the wells of the antibody-coated plate in duplicate. The plate was incubated at room temperature (RT) overnight. After washing five times, 100 µL of peroxidase, horseradish (HRP)-conjugated detection antibodies were added to each well and incubated at RT for 30 min. Absorbance at 450 nm in each well was measured by a microplate reader (Perkin Elmer, USA) after developing with 100 µL of H\(_2\)SO\(_4\)-Tau concentrations in the tested CSF samples were calculated based on a tau standard curve.

**RT-QuIC assays**

Real-time quaking induced conversion (RT-QuIC) assay was performed according to the working procedures described previously.\(^{13}\) Briefly, each reaction contained 10 µg of a recombinant hamster protein (rHaPrP90-231), 1X phosphate buffer saline (PBS), 170 mM NaCl, 1 mM EDTA, 0.01 mM thioflavin T (ThT) and 0.001% SDS, together with 15 µL of the CSF sample, in a final volume of 100 µL. The assay was conducted in a black 96-well, optical-bottomed plate (Nunc, 265301) on a BMG FLUOSTar Plate Reader (BMG LABTECH). The following were the working conditions: temperature, 55°C; vibration speed, 700 revolution per minute (rpm); vibration/incubation time, 60/60 s; and total reaction time, 60 hours. The ThT fluorescence value (excitation wavelength, 450 nm; emission wavelength, 480 nm) of each reaction was automatically counted every 45 min and further presented as relative fluorescence units. Each sample was tested in quadruplicate simultaneously. The cut-off value was set as the mean value of the negative controls plus 10 times the SD. A sample was considered to be positive when ≥2 wells revealed positive reaction curves. A 10\(^{-5}\) diluted brain homogenate of the scrapie agent 263K-infected hamster was used as the positive control, while 10\(^{-5}\) diluted brain homogenate of the normal hamster was used as the negative control.

**Statistical assays**

Statistical analyses were performed using the SPSS V.11.5 statistical software program.

**Patient and public involvement**

No patients were involved.

**RESULTS**

**General information**

Since 2006, more than 200 cases of genetic human prion diseases have been identified and diagnosed via CNS-CJD, which consisted of 19 different subtypes of mutations in \textit{PRNP}.\(^{13,16}\) Among them, 16 patients with E196A gCJD and 5 patients with E196K gCJD were identified via the Chinese National CJD Surveillance System during the period 2006–2020. The first E196A and E196K gCJD cases were reported in 2011 and 2009, respectively (figure 1A).
Afterwards, more cases of E196A gCJD were diagnosed, particularly since 2015, and peaked in 2017. E196K gCJD cases were markedly less frequent, with one case reported in 2015, 2017, 2019 and 2020, respectively. The gender (male:female) distribution of E196A and E196K cases was 1:0.78 (9:7) and 1:1.5 (2:3). The age of onset of E196A cases varied from 43 to 76 years old, with a median of 61 years, while that of E196K cases varied from 61 to 77 years old, with a median of 67 years. The peak age of onset in E196A patients was 50–59 years and 60–69 years, which looked younger than that of E196K patients (figure 1B). Analysis of age of onset of patients based on gender found that the median age of onset among E196A male patients was older than female patients (65 years vs 56 years), while the median age of onset among E196K male patients was younger than female patients (62.5 years vs 73.5 years). No significant geographical-associated and occupational-associated phenomenon was observed.

Clinical features
The clinical, genetic and laboratory data of 16 cases of E196A gCJD and 5 cases of E196K gCJD are summarised in table 1. The intervals from onset to diagnosis varied largely, ranging from 1 to 13 months. Majority of the patients (18 of 21) were diagnosed within 6 months of onset, without notable differences between the E196A and E196K groups. Most data on clinical manifestations, examinations and laboratory tests of these patients were obtained during the period of hospitalisation and were referred to CNS-CJD. Some information was collected via follow-up surveys after discharge. Patients with E196A mutation displayed two to four major symptoms (table 2). Dementia (cognitive decline and memory loss) was the complaint in 68.8% (11 of 16) cases, followed by mental problems (emotional lability and anxiety) in 62.5% (10 of 16), extrapyramidal dysfunction (unsteady gait, drooling and shaking of limbs) in 43.8% (7 of 16) and cerebellum disorder (ataxia, speech dysgraphia and dysmetria) in 43.8% (7 of 16). Three patients described cortical blindness and one complained of paraesthesia. A slight difference in major symptoms was observed between gender and between young (<60 years) and elderly (>60 years) patients, but without statistical significance. In contrast, five patients with E196K mutation showed fewer initial disorders, limited to dementia (4 of 5) and mental problems (2 of 5). Other symptoms were rarely recorded.

Along with progression, rapid progressive dementia was reported in all patients regardless of mutation, E196A or E196K. Other sCJD-associated symptoms and signs were also observed gradually. In the group of patients with E196A mutation, five patients were recorded to have four major sCJD-associated symptoms, seven cases with three symptoms and three cases with two symptoms. Only one case (case 9) did not show the four major symptoms, although the patient had clear mental problems (table 1). The rates of detection of myoclonus, cerebellum and visual disorders, pyramidal and extrapyramidal symptoms, and mutism were 68.8% (11 of 16), 81.3% (13 of 16), 87.5% (14 of 16) and 62.5% (10 of 16), respectively (figure 2A). In the group of patients with E196K mutation, all five patients showed myoclonic movement, while none reported cerebellum and visual disorders. Four cases displayed pyramidal and extrapyramidal symptoms and two had mutism (table 1 and figure 2B).

EEG and MRI features
All patients received electroencephalogram (EEG) and MRI examinations at least one time. In the group of patients with E196A mutation, four patients recorded typical periodic sharp wave complexes (PSWCs) on EEG, seven showed different abnormalities but without PSWCs, and another five cases had uncertain PSWCs (table 1 and...
Table 1  Main features of Chinese patients with E196A and E196K gCJD

<table>
<thead>
<tr>
<th>Type</th>
<th>Case</th>
<th>Gender, age of onset, province</th>
<th>Initial disorders</th>
<th>Dementia*</th>
<th>Other major CJD-associated problems†</th>
<th>EEG</th>
<th>MRI</th>
<th>CSF</th>
<th>Polymorphism</th>
<th>Duration (months)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>PSWC</td>
<td>I</td>
<td>II</td>
<td>III</td>
<td>IV</td>
</tr>
<tr>
<td>E196A</td>
<td>1</td>
<td>M, 70s, Jilin</td>
<td>Mental problem, + dementia</td>
<td>+ + + + +</td>
<td>NR</td>
<td>–</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td></td>
<td>2</td>
<td>F, 50s, Heilongjiang</td>
<td>Dementia, cerebellum disorder</td>
<td>+ – + + –</td>
<td>NC</td>
<td>NR</td>
<td>+</td>
<td>+</td>
<td>–</td>
<td>+</td>
</tr>
<tr>
<td></td>
<td>3</td>
<td>F, 50s, Zhejiang</td>
<td>Cerebellum disorder</td>
<td>+ + + + –</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>–</td>
<td>+</td>
</tr>
<tr>
<td></td>
<td>4</td>
<td>F, 60s, Shanghai</td>
<td>Paraesthesia, cerebellum disorder</td>
<td>+ + + + +</td>
<td>NC</td>
<td>–</td>
<td>–</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td></td>
<td>5</td>
<td>M, 50s, Guangdong</td>
<td>Dementia, mental problem, extrapyramidal dysfunction</td>
<td>+ – + + –</td>
<td>–</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>–</td>
<td>+</td>
</tr>
<tr>
<td></td>
<td>6</td>
<td>M, 60s, Guangdong</td>
<td>Cerebellum disorder, alalia</td>
<td>+ + + + –</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>–</td>
<td>+</td>
</tr>
<tr>
<td></td>
<td>7</td>
<td>M, 72 years, Jilin</td>
<td>Dementia, mental problem, extrapyramidal dysfunction</td>
<td>+ – + + –</td>
<td>NC</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td></td>
<td>8</td>
<td>M, 60s, Chongqing</td>
<td>Dementia, cerebellum disorder, extrapyramidal dysfunction</td>
<td>+ + + + –</td>
<td>+</td>
<td>+</td>
<td>–</td>
<td>+</td>
<td>–</td>
<td>+</td>
</tr>
<tr>
<td></td>
<td>9</td>
<td>M, 60s, Guangdong</td>
<td>Dementia, mental problem</td>
<td>– – – – –</td>
<td>+</td>
<td>+</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>+</td>
</tr>
<tr>
<td></td>
<td>10</td>
<td>M, 60s, Chongqing</td>
<td>Dementia, cerebellum disorder, extrapyramidal dysfunction, mental problem</td>
<td>+ + + + –</td>
<td>+</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>+</td>
<td>–</td>
</tr>
<tr>
<td></td>
<td>11</td>
<td>F, 50s, Yunnan</td>
<td>Dementia, mental problem, extrapyramidal dysfunction</td>
<td>+ + + + +</td>
<td>+</td>
<td>–</td>
<td>+</td>
<td>ND</td>
<td>–</td>
<td>M/M</td>
</tr>
<tr>
<td></td>
<td>12</td>
<td>F, 70s, Fujian</td>
<td>Dementia, mental problem, extrapyramidal dysfunction</td>
<td>– – + + –</td>
<td>+</td>
<td>+</td>
<td>–</td>
<td>+</td>
<td>ND</td>
<td>M/M</td>
</tr>
</tbody>
</table>

Continued
Table 1  Continued

<table>
<thead>
<tr>
<th>Type</th>
<th>Case</th>
<th>Gender, age of onset, province</th>
<th>Initial disorders</th>
<th>Dementia*</th>
<th>Other major CJD-associated problems†</th>
<th>EEG</th>
<th>MRI</th>
<th>CSF</th>
<th>Polymorphism</th>
<th>Duration (months)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>I</td>
<td>II</td>
<td>III</td>
<td>IV</td>
<td>PSWC</td>
<td>Ribbon-like signal</td>
<td>High signals in caudate/putamen</td>
</tr>
<tr>
<td>13</td>
<td>F, 50s, Jilin</td>
<td>Dementia, mental problem, cortical blindness, extrapyramidal dysfunction</td>
<td>+</td>
<td>−</td>
<td>+</td>
<td>+</td>
<td>NC</td>
<td>−</td>
<td>−</td>
<td>+</td>
</tr>
<tr>
<td>14</td>
<td>M, 60s, Fujian</td>
<td>Dementia, cortical blindness</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>−</td>
<td>+</td>
<td>−</td>
<td>−</td>
<td>+</td>
</tr>
<tr>
<td>15</td>
<td>F, 40s, Zhejiang</td>
<td>Mental problem, cortical blindness</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>−</td>
<td>+</td>
<td>+</td>
<td>−</td>
<td>ND</td>
</tr>
<tr>
<td>16</td>
<td>M, 50s, Sichuan</td>
<td>Dementia, cerebellum disorder, mental problem</td>
<td>+</td>
<td>−</td>
<td>+</td>
<td>+</td>
<td>NC</td>
<td>+</td>
<td>−</td>
<td>+</td>
</tr>
<tr>
<td></td>
<td>F196K</td>
<td>F, 70s, Jilin</td>
<td>Dementia</td>
<td>+</td>
<td>+</td>
<td>−</td>
<td>+</td>
<td>+</td>
<td>−</td>
<td>−</td>
</tr>
<tr>
<td>2</td>
<td>F, 70s, Beijing</td>
<td>Dementia</td>
<td>+</td>
<td>+</td>
<td>−</td>
<td>−</td>
<td>−</td>
<td>+</td>
<td>+</td>
<td>−</td>
</tr>
<tr>
<td>3</td>
<td>F, 70s, Shanghai</td>
<td>Mental problem, dementia</td>
<td>+</td>
<td>−</td>
<td>+</td>
<td>+</td>
<td>−</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>4</td>
<td>M, 60s, Hebei</td>
<td>Mental problem</td>
<td>+</td>
<td>+</td>
<td>−</td>
<td>−</td>
<td>−</td>
<td>+</td>
<td>+</td>
<td>−</td>
</tr>
<tr>
<td>5</td>
<td>M, 60s, Fujian</td>
<td>Dementia</td>
<td>+</td>
<td>+</td>
<td>−</td>
<td>+</td>
<td>+</td>
<td>−</td>
<td>+</td>
<td>−</td>
</tr>
</tbody>
</table>

*Rapid progressive dementia.
†I: myoclonic movement; II: cerebellum and visual disturbances; III: pyramidal or extrapyramidal dysfunction; IV: akinetic mutism.
CJD, Creutzfeldt-Jakob disease; CSF, cerebrospinal fluid; EEG, electroencephalogram; F, female; gCJD, genetic Creutzfeldt-Jakob disease; M, male; NC, uncertain; ND, not done; NR, not recorded; PSWC, periodic sharp wave complex; RT-QuIC, Real-time quaking induced conversion.
The positivity rate of definite PSWC on EEG in E196A cases was 25%. In the group of patients with E196K, none of the five patients showed typical PSWCs (figure 3A). The sCJD-associated MRI abnormalities (ribbon-like signal on diffusion weighted imaging (DWI) and/or high signals in the caudate/putamen) were observed in 68.8% (11 of 16) of E196A cases and 80% (4 of 5) of E196K cases (figure 3B). Ribbon-like signals (9 out of 14 cases with E196A and 4 with E196K) were more frequently detected than high signals in the caudate/putamen (6 cases with E196A and 2 cases with E196K) (table 1).

**PRNP gene sequencing**

Mutations at codon 196 in one PRNP allele of the patients were verified by direct sequencing of the PCR products, which was routinely repeated at least two times with newly extracted DNAs. Sixteen suspected CJD cases contained a missense mutation at codon 196 of the PRNP gene, leading to a substitution of glutamic acid by alanine, while five cases had a mutation causing substitution of glutamic acid by lysine. No additional nucleotide exchanges were found in other regions of the PRNP sequences of those cases. All patients had methionine homozygosity at codon 129 (M129M). Out of 16 E196A cases, 15 had glutamic acid homozygosity at codon 219 (E219E) and 1 case (case 12) had glutamic acid/lysine heterozygosity (E219K). All five E196K cases had the sequencing data of codon 219, revealing E219E.

**CSF protein 14-3-3 and tau**

Lumbar puncture was conducted in all patients. Routine items (cells, proteins, glucose, electrolytes, etc) on CSF biochemistry were all in the normal ranges. Western blots for CSF 14-3-3 were positive in 75% (12 of 16) of E196A cases and 60% (3 of 5) of E196K cases (figure 3C). The total tau level in the CSF samples from 10 cases with E196A and 3 cases with E196K (table 1) was measured with a commercial ELISA kit and a tau level higher than 1400 pg/mL was considered positive based on previous studies. Eight (out of ten) cases with E196A mutation and two (out of three) cases with E196K mutation were positive (figure 3D).

**RT-QuIC features**

All cases with E196A and E196K mutations in this study were subjected to RT-QuIC tests with 15 µL CSF sample each, using a recombinant truncated hamster PrP protein amino acid 90-231 (rHaPrP90-231) as the substrate. Under our experimental condition, 37.5% (6 of 16) of E196A gCJD cases and 60% (3 of 5) of E196K gCJD cases were positive on CSF RT-QuIC (figure 4 and table 1). There was

<table>
<thead>
<tr>
<th>Table 2</th>
<th>Major symptoms of patients with genetic Creutzfeldt-Jakob disease with E196A or E196K mutation</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><strong>E196A</strong></td>
</tr>
<tr>
<td>Major symptoms</td>
<td>Total (n=16) n (%) Male (n=9) n (%) Female (n=7) n (%)</td>
</tr>
<tr>
<td>Dementia</td>
<td>11 (68.8) 7 (77.8) 4 (57.1) 5 (71.4) 6 (66.7)</td>
</tr>
<tr>
<td>Mental problem</td>
<td>10 (62.5) 6 (66.7) 4 (57.1) 5 (71.4) 5 (55.6)</td>
</tr>
<tr>
<td>Extrapyramidal dysfunction</td>
<td>7 (43.8) 4 (44.4) 3 (42.9) 3 (42.9) 4 (44.4)</td>
</tr>
<tr>
<td>Cerebellum disorder</td>
<td>7 (43.8) 4 (44.4) 3 (42.9) 3 (42.9) 3 (33.3)</td>
</tr>
<tr>
<td>Cortical blindness</td>
<td>3 (18.8) 1 (11.1) 2 (28.6) 2 (28.6) 1 (11.1)</td>
</tr>
</tbody>
</table>

Figure 2 Positive rates and case numbers of four major sCJD-associated symptoms in Chinese patients with (A) E196A and (B) E196K genetic Creutzfeldt-Jakob disease. neg, negative; pos, positive; sCJD, sporadic Creutzfeldt-Jakob disease.
no marked difference in the positive conversion time and in the peak of the reactive curves in RT-QuIC between the two groups.

**Survival time**

By the end of July 2020, 12 cases with E196A had died, 3 cases were alive and 1 was lost, while 4 cases with E196K had died and 1 was lost (table 1). As shown in figure 5A, the duration of survival of patients with E196A gCJD varied from 2 to 28 months, with a median survival of 6.5 months. Half of the dead cases died within 5 months of onset. All four dead cases of E196K gCJD died within 5 months of onset, with a median of 4.5 months (range 2–5 months). Analysis of median survival between the two types of gCJD revealed statistical difference (p=0.018). Three E196A cases were alive, with a clinical duration of 36, 20 and 3 months, respectively (table 1). Further, the survival time of 12 dead cases with E196A was analysed based on gender and age of onset. Male patients (n=6) showed much shorter survival time (median: 4 months, range 2–10 months) than female patients (n=6) (median: 15 months, range 4–28 months) (figure 5B), with significant difference (p=0.009). Senior cases (≥60 years, n=7) had much shorter survival time (median: 4 months, range 2–8 months) than the younger ones (<60 years, n=5) (figure 5C), showing significant difference (p=0.001).

**DISCUSSION**

Human genetic prion diseases display apparent diversity in clinical and laboratory features. In this study, we have comparatively analysed the features of 16 Chinese patients with E196A gCJD and 5 patients with E196K gCJD in terms of demographics, clinical, EEG and MRI, and CSF laboratory tests. Unfortunately, we did not have any brain specimens, either postmortem or biopsy, from the patients so the neuropathological and pathogenic...
prion protein (PrPSc) features of Chinese patients with E196A and E196K gCJD remain unclear. Also, there was a limited number of enrolled patients, especially patients with E196K mutation, which may have resulted in observational bias. Generally, the clinical features of both E196A and E196K gCJD cases are like sCJD, for example, displaying rapid progressive dementia and other major manifestations, and high positive rates of MRI abnormalities, CSF 14-3-3 and total tau. However, the E196A and E196K cases in this study also show some degree of differences in some aspects. The age of onset of E196A patients is similar to Chinese patients with sCJD, however, the five E196K cases were relatively older. E196A cases showed more diverse major symptoms, while symptoms in E196K cases were confined to dementia and mental problems. Cerebellum and visual disturbances were frequent in E196A cases, but not observed in E196K patients. PSWCs on EEG were not observable in all E196K cases but were recordable in a small portion of E196A cases. Additionally, E196K cases seem to have higher ratios of positive CSF RT-QuIC than E196A cases. These observations may be biased due to the small cohort (N=21). In fact, E196K gCJD has been reported in many European countries. Unlike the five Chinese cases, the phenotypes in European patients are more diverse, such as having cerebellum problems and PSWC on EEG in a portion of patients.15–18 We have to say that majority of the data and specimens of the patients in this study were collected and tested with a median of 7.5 months.6 16–19

Figure 5  Survival time of Chinese patients with E196A and E196K gCJD. (A) Survival graph of E196A and E196K gCJD cases. (B) Survival graph of E196A cases based on gender. (C) Survival graph of E196A cases based on age of onset. Median survival is indicated in the graphs. gCJD, genetic Creutzfeldt–Jakob disease.

Our data show about three times more E196A cases than E196K cases in the past 10 years. As we do not know the frequency of these two genotypes in general Han Chinese, such diversity in case numbers reflects only the difference in disease occurrence and identification. None of the family members from the 21 patients undertook assays for PRNP sequencing. Thereby, we are also unable to speculate the exact penetrance of these two mutations. The penetrance of mutations in PRNP has been evaluated in several studies.4 21 22 However, the exact pathogenicity of many rare mutations remains poorly understood. The penetrance of PRNP mutations is associated with family history. Low-penetrance mutations seem to have low rates of positive family history.21 None of the cases in this study recorded family history, which might highlight the low penetrance of E196A and E196K mutations. The penetrance of PRNP mutations is also influenced by age. One example is the Sephardic E200K mutation carrier, the penetrance of which is 70% at age 70 and close to 100% at age 85.23 Screening PRNP mutations in senior patients with neurological problems will be beneficial in identifying the typical gCJD. On the other hand, relatively late age of onset, such as the Chinese E196K gCJD cases who had a short duration of survival in this study, may also increase the probability of case loss due to death or misdiagnosis of other diseases. Genomic assays, such as whole exome analysis, on patients with E196 mutations in the future may be beneficial in exploring possible modifiable risk factors associated with the disease process.

E196K gCJD was first reported in 2000 and was described in six German patients,16 while E196A gCJD was reported late in China.24 Based on the literature, dozens of E196K gCJD cases have been described in European countries, such as in Germany, Italy, France and UK.2 4 6 16–18 25 In contrast, E196K mutation is rarely reported in East Asians, besides the Chinese cases described previously6 and in this study. On the other hand, E196A mutation seems to be confined to Chinese and to be extremely rare in other
CONCLUSION
E196A gCJD is now the fourth most frequently observed genetic prion disease in China. This is the largest report to date of gCJD with mutations at codon 196. The diversity in clinical and laboratory tests between patients with E196A and E196K mutations indicates that substitutions of different amino acids at the same position with PrP may associate with different clinical phenotypes.

Author affiliations
1 State Key Laboratory for Infectious Disease Prevention and Control, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases (Zhenghai University), National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China
2 Center for Global Public Health, Chinese Center for Disease Control and Prevention, China CDC (CCDC) under protocol 2011ZX10004-101.
3 Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, China
4 Center for Global Public Health, Chinese Center for Disease Control and Prevention, Beijing, China

Acknowledgements
We thank colleagues from CDC in all provinces and cities.

Contributors
QShi contributed to study design, performed the assays and data analysis, and prepared the manuscript. KX, WZ, CG and Y-PD contributed to design, performed the assays and data analysis, and prepared the manuscript. KX, WZ, CG and Y-PD contributed to design, performed the assays and data analysis, and prepared the manuscript. KX, WZ, CG and Y-PD contributed to design, performed the assays and data analysis, and prepared the manuscript.

Funding
This work was supported by Chinese National Natural Science Foundation grants (81630062), as well as grants (2019SKLID501, 2019SKLID603, 2019SKLID307) from the State Key Laboratory for Infectious Disease Prevention and Control, China CDC.

Competing interests
None declared.

Patient and public involvement
Not applicable.

Patient consent for publication
Not required.

Ethics approval
Usage of the surveillance data of patients with E196A and E196K gCJD in Chinese National CJD Surveillance System (CNS-CJD) has been approved by the Research Ethics Committee of the National Institute for Viral Disease Control and Prevention, China CDC (CCDC) under protocol 2011ZX10004-101

Provenance and peer review
Not commissioned; externally peer reviewed.

Data availability statement
Data are available on reasonable request. All data relevant to the study are included in the article or uploaded as supplementary information.

Open access
This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iDs
Qi Shi http://orcid.org/0000-0002-6282-9864
Xiao-Ping Dong http://orcid.org/0000-0002-7022-0418

REFERENCES
15 Eigenbrod S, Frick P, Giese A, et al. Comprehensive neuropathologic and molecular analysis of different amino acids at the same position with PrP may associate with different clinical phenotypes.
16 Competing interests
None declared.

Patient and public involvement
Not applicable.

Patient consent for publication
Not required.

Ethics approval
Usage of the surveillance data of patients with E196A and E196K gCJD in Chinese National CJD Surveillance System (CNS-CJD) has been approved by the Research Ethics Committee of the National Institute for Viral Disease Control and Prevention, China CDC (CCDC) under protocol 2011ZX10004-101.

Provenance and peer review
Not commissioned; externally peer reviewed.

Data availability statement
Data are available on reasonable request. All data relevant to the study are included in the article or uploaded as supplementary information.

Open access
This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iDs
Qi Shi http://orcid.org/0000-0002-6282-9864
Xiao-Ping Dong http://orcid.org/0000-0002-7022-0418

REFERENCES